**9. Summary**

Dyslipidemia is one of the major risk factors for macrovascular disease leading to CVD in type 2 diabetes.

In type 2 diabetes patients with dyslipidemia, alteration in lipid distribution and platelet abnormalities increased risk of acquiring CVD.

Patients with type 2 diabetes with one of the following; dyslipidemia, family history of coronary heart disease, hypertension, smoking and albuminuria are at increased risk of CVD, thus eligible for primary prevention strategy of CVD.

With limited evidence, proper justification and clinical judgments of benefit versus risk, aspirin plays a key role as antiplatelet agent in primary prevention of CVD in patients with type 2 diabetes with dyslipidemia.

Patients with type 2 diabetes and dyslipidemia receiving aspirin for primary prevention strategy should be monitored for effectiveness of treatment (sign and symptoms of CVD) and adverse effects (stomach pain, heartburn, nausea and bleeding tendency).
